IBM and Cleveland Clinic Use Quantum Computing to Tackle Protein Research

FomoAnxiety · 2026-03-25T00:51:49+00:00

IBM and Cleveland Clinic are collaborating to leverage quantum computing for protein analysis, enhancing drug development. This hybrid method shows promise in efficiently solving complex protein problems, which could revolutionize medicine.

FomoAnxiety

2026-03-25 00:51:49

Abstract generation in progress

Tech giant IBM IBM -3.16% ▼ is working with the Cleveland Clinic to study how quantum computing can help scientists better understand proteins, which are essential for how the human body works. Normally, researchers use traditional computers for this, but some protein problems are too complex to solve that way. Because of this, the team is combining quantum and classical computing to analyze how proteins fold and behave.

Claim 30% Off TipRanks Premium

Trade IBM with leverage
New trading tool for IBM bulls/bears
Forget margin or options. Here’s how the pros trade IBM

This is important since understanding protein structure plays a key role in developing new treatments and medicines. Interestingly, the approach focuses on using each type of computer for what it does best. Quantum computers handle the most difficult part of the problem, such as finding the most stable structure of a protein, while traditional computers take care of the rest. As a result, this hybrid method makes the overall process more efficient.

Indeed, in early testing, researchers were able to simulate parts of real proteins, which shows that this approach can produce useful and realistic results. Looking ahead, the technology could eventually help scientists design better drugs, understand diseases more clearly, and bring new treatments to patients faster. While it is still early, this shows how quantum computing could become an important tool in the future of medicine.

Is IBM a Buy, Sell, or Hold?

Turning to Wall Street, analysts have a Moderate Buy consensus rating on IBM stock based on 11 Buys, six Holds, and zero Sells assigned in the past three months, as indicated by the graphic below. Furthermore, the average IBM price target of $332.94 per share implies 38.4% upside potential.

Disclaimer & DisclosureReport an Issue

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.